NBB-116 - Oral Drug Candidate for Alzheimer’s Disease

NBB-116 is an orally available small-molecule drug candidate being developed by NeuroBB for the treatment of Alzheimer’s disease. NBB-116 is designed to inhibit PDE5 and activate the cGMP-PKG-CREB signaling pathway, with the aim of improving cognitive function and addressing key pathological features of Alzheimer’s disease. The candidate is currently in preclinical development, and NeuroBB is pursuing global licensing and co-development opportunities with pharmaceutical and biotechnology partners.